FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization
FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization Verquvo is the first soluble guanylate cyclase stimulator drug cleared by FDA to treat heart failure January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat). It is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics. The drug is supposed to reduce the risk of cardiovascular death and heart failure hospitalization in indicated patients with symptomatic chronic hea...
Source: dicardiology.com